SHARESIFT
Healthcare · data ~15-min delayed
140.06 USD +0.63%
| Price | 140.06 USD |
| Day change | +0.63% |
| Market cap | 9.06B |
| 52-week range | 62.24 – 160.81 |
| P/E (trailing) | 134.7 |
| Dividend yield | 0.00% |
| Payout ratio | 0.00% |
| Return on equity | 10.98% |
| Debt / equity | 1% |
| Beta | 1.79 |
| Sector | Healthcare |
| Value score | 27 / 100 |
How the value score is calculated: 13 published tests, weighted to 100.
Protagonist Therapeutics, Inc. (PTGX) scores 27/100 on this site's value model, in the lower band: most of the valuation measures it checks sit on the richer side. It trades at 134.7 times trailing earnings and is classified in Healthcare. It does not currently pay a dividend. Return on equity is 11%, with debt at 1% of equity. On its filings it passes 2 of the nine Piotroski checks, which points to deteriorating fundamentals. These are automated readings of reported figures, not a recommendation.
Piotroski F-Score 2 / 9 — nine pass/fail checks on profitability, leverage and efficiency, comparing the latest financial year with the one before.
Updated · prices ~15-min delayed, fundamentals as last reported
Open full interactive analysis →See how it ranks: US stocks by value score
Value scoring · Piotroski F-Score · Altman Z · technicals · dividends — free, no sign-up.